Research Categories
- Anesthesia
- Arthroscopy
- Biologics/Biomaterials
- Cancer Devices
- Cardiovascular
- Cosmetic Devices
- Dental
- Diabetes
- Diagnostics
- Dialysis
- Drug Delivery
- Ear, Nose, Throat
- Endoscopy
- Gastrointestinal (GI)
- General Surgery
- Gynecology Devices
- Healthcare IT
- Hearing Devices
- Imaging
- Immunology
- Infusion Therapy
- Laparoscopy
- Minimally Invasive Surgery
- Neurology Devices
- Oncology
- Operating Room Equipment
- Ophthalmics Devices
- Orthopedics
- Patient Monitoring
- Peripheral Vascular
- Respiratory Devices
- Robotics & Navigation
- Sleep Apnea & Diagnostics
- Spine
- Stents
- Tissue Repair
- Urology
- Vascular Access
- Video Hi-Tech
- Women's Health
- Wound Care
Hyaluronic Acid
Showing all 9 results
Orthopedic Biomaterials Market Size, Share & Trends Analysis | United States | 2024-2030 | MedSuite | Includes: Bone Graft Substitutes, Orthopedic Growth Factors, Cellular Allografts, and 3 more
The full report suite on the U.S. market for orthopedic biomaterials includes bone graft substitutes, which are represented by allografts, demineralized bone matrices (DBMs), xenografts and synthetic bone graft markets. The report also includes orthopedic growth factors; cellular allografts; orthopedic cell therapy, represented by bone marrow aspirate concentrate and platelet-rich plasma; hyaluronic acid (HA) viscosupplementation in single-, two-, three- and five-injection cycles; and, finally, orthopedic cartilage repair. Cartilage repair is represented by the osteochondral allograft, meniscal allograft, autologous chondrocyte implantation, particulated juvenile allograft and microfracture adjunct segments.
more...Orthobiologics Market Analysis, Size, Trends | China | 2020-2026 | MedSuite
In 2020, the Chinese orthobiologics market size was valued at $460.7 million, with over 424,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 6% to reach $690.8 million in 2026. Throughout this medical market research, we analyzed 28 orthobiologics companies across China […]
more...Orthobiologics Market Analysis, Size, Trends | Japan | 2020-2026 | MedSuite
In 2020, the Japanese orthobiologics market size was valued at $426.9 million, with over 221,000 bone grafting procedures performed every year. The market size is expected to fluctuate over the forecast period with a -0.4% compound annual growth rate (CAGR). Throughout this medical market research, we analyzed 16 orthobiologics companies across Japan and used our […]
more...Orthobiologics Market Analysis, Size, Trends | India | 2020-2026 | MedSuite
In 2020, the Indian orthobiologics market size was valued at $76.2 million, with over 520,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 12.4% to reach $172.3 million in 2026. Throughout this medical market research, we analyzed 23 orthobiologics companies across India […]
more...Orthobiologics Market Analysis, Size, Trends | South Korea | 2020-2026 | MedSuite
In 2020, the South Korean orthobiologics market size was valued at $141.6 million, with over 200,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 3.6% to reach $181.5 million in 2026. Throughout this medical market research, we analyzed 16 orthobiologics companies across […]
more...Orthobiologics Market Analysis, Size, Trends | Australia | 2020-2026 | Medsuite
In 2020, the Australian orthobiologics market size was valued at $63.8 million, with over 29,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 4.9% to reach $89.4 million in 2026. Throughout this medical market research, we analyzed 48 orthobiologics companies across Australia […]
more...Orthopedic Hyaluronic Acid Market Analysis | Canada | 2016-2022 | MedCore
One of the market limiters for the Canadian HA market is the reimbursement structure. None of the products are covered under standard healthcare plans and must be purchased directly or through extended healthcare coverage or private insurance. Thus, some patients opt out to receiving cortisone injections; these are reimbursed by standard healthcare and are a more affordable choice.
One of the factors that contributed positively to this market is ever expanding indication. The market originally started with treating osteoarthritis (OA) of the knee, since then some products expanded into hip, shoulder, a number of small joints, as well as assisting with post-surgery joint recovery.